About this trial
The purpose of the project is to investigate exercise performance in humans following bronchodilation induced by acute inhalation of beta2-agonist indacaterol + mometasonefuroate
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Age 18-39
Physically active > 5 h weekly
Maximal oxygen consumption classified as high or very high
Disqualifiers
Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
ECG abnormality
ACQ score > 1.5
Severe bronchial hyperreactivity as determined by mannitol test
Trial design
Crossover
Treatments tested in this trial
Indacaterol and Mometasonefluroate (low dose)
DrugParticipants are administered 125 µg indacaterol + mometasonefluroate
Placebo
DrugParticipants are administered placebo
Indacaterol and Mometasonefluroate (high dose)
DrugParticipants are administered 500 µg indacaterol + mometasonefluroate
Treatment groups
Trial outcomes
Primary outcomes
Power output during sprint testing
Power output measured in Watts during a sprint on a bike ergometer
Secondary outcomes
Power output during time trial
Mean power output measured in Watts during a time trial on a bike ergometer
Forced Expiratory Volume in 1 second (FEV1)
FEV1 measured by spirometry
Quadriceps strength
Maximal torque (Nm) achieved during isometric contraction
Respiratory muscle function
Mouth inspiratory and expiratory pressures (MD Diagnostics, RP-check, handheld respiratory pressure meter)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Morten Hostrup, PhD
Lead sponsor
University of Copenhagen
Sponsor institution